DUBLIN, Ireland, July 16, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ...

DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of ...

The oral and IV formulations of Xenleta (lefamulin), a first-in-class pleuromutilin antibiotic, have been made available in the US by Nabriva Therapeutics. The oral and intravenous (IV) formulations ...

First IV and oral antibiotic with novel mechanism of action approved by the FDA in nearly two decades, targets the most common CABP pathogens and supports antibiotic stewardship DUBLIN, Ireland, Sept.

Ireland-headquartered biotech Nabriva has picked up its first product approval, getting an FDA okay for antibiotic Xenleta as a treatment for community-acquired bacterial pneumonia (CABP). Xenleta ...

LONDON--(BUSINESS WIRE)-- WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a ...

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of ...

European Commission decision anticipated in the second half of 2020 DUBLIN, Ireland, May 29, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) announced today that the Committee for ...

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up with the challenge. Now, with the FDA’s approval of a new antibiotic for bacterial pneumonia, some of that may change.

Meitheal Pharmaceuticals is growing its specialty biopharmaceutical portfolio through a licensing agreement for a novel antibiotic approved to treat community-acquired bacterial pneumonia. The Chicago ...

Lefamulin 150mg (in 15mL of 0.9% sodium chloride); per vial; soln for IV infusion after dilution. Xenleta is a systemic pleuromutilin antibacterial that inhibits bacterial protein synthesis through ...

LONDON--(BUSINESS WIRE)--WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA ® (lefamulin) on a ...